Skip to main content

Table 1 Characteristics of study population and comparison with main study population

From: Impaired myocardial perfusion is associated with increasing end-systolic- and end-diastolic volumes in patients with non-ischemic systolic heart failure: a cross-sectional study using Rubidium-82 PET/CT

  Patients in PET-study (N = 151) Remaining study population without COPD (N = 819) P-value
Age (IQR) – yr. 62 (55–69) 63 (55–71) 0.33
Male sex – no. (%) 104 (69) 608 (74) 0.17
Body-mass index (IQR) – kg/m2 26.6 (24.1–29.8) 26.9 (23.9–30.2) 0.71
NT-pro-BNP (IQR) – pg/ml 851 (466–1848) 1220 (618–2274) < 0.01
eGFR (IQR) – ml/min/ 1.73 m2 78 (63–94) 73 (58–92) 0.03
Left ventricular ejection fraction (IQR) – % 25 (20–31) 25 (20–30) 0.04
Coexisting conditions – no. (%)
 Diabetes mellitus – no. (%) 19 (13) 160 (20) 0.04
 Hypertension 47 (31) 257 (31) 0.94
 Left bundle branch block – no. (%) 83 (60) 480 (65) 0.22
Cause of heart failure – no. (%)
 Idiopathic 118 (78) 615 (75) 0.32
 Valvular 9 (6) 31 (4)
 Hypertension 11 (7) 88 (11)
 Other 13 (9) 85 (10)
Medications – no. (%)
 ACE-inhibitor or ARB 149 (99) 785 (96) 0.09
 Beta blocker 145 (96) 747 (91) 0.05
 Aldosterone receptor antagonist 86 (57) 471 (58) 0.90
 Statins 60 (40) 356 (43) 0.39
 Anticoagulation treatment 54 (36) 314 (38) 0.55
 Acetylsalicylic acid 53 (35) 308 (38) 0.56
Device therapy – no. (%)
 CRT 75 (50) 496 (61) 0.01
  1. COPD chronic obstructive pulmonary disease, IQR interquartile range, NT-proBNP N-terminal pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate, ACE angiotensin-converting enzyme, ARB angiotensin-receptor blocker, CRT cardiac resynchronization therapy. Two-sided P value determined by Wilcoxon two-sample or chi-square test